Eurobio Scientific: EXCEPTIONAL 2020 TURNOVER OF € 189 MILLION (+
220%)
EXCEPTIONAL 2020 TURNOVER OF € 189
MILLION (+ 220%)
• A leading player in diagnostics able to
adapt and meet the needs generated by the health
crisis• Strong momentum in traditional activities
(+ 22% to € 71.9 million)• Acceleration of the
growth strategy thanks to improved visibility and greatly increased
financial resources
Paris, January 25, 2021 - 5:45 p.m.
Eurobio Scientific (FR0013240934, ALERS,
PEA-PME eligible), a leading French group in in vitro
medical diagnostics and life sciences, today presents its
consolidated annual turnover as of December 31, 2020.
Exceptional growth of + 220% to € 189m
Eurobio Scientific recorded exceptional sales of
€ 188.9 million for the 2020 financial year, an increase of 220%
compared to the previous financial year. More than 60% of these
sales (€ 117m) are related to COVID-19 diagnostic tests and
instruments.
Eurobio Scientific was able to quickly deploy on
its market of specialized private and hospital laboratories for
medical biology, a whole range of in vitro diagnostic tests for the
detection of the SARS-Cov-2 coronavirus, and thus support efforts
to manage the health crisis by public and private actors. This
performance was made possible thanks to long-term partnerships with
its suppliers, as well as the experience and responsiveness of its
R&D department and its sales teams, all integrated within an
organization already adapted and ready to manage a strong
growth.
During the financial year, Eurobio Scientific
continuously delivered various reagents necessary for the diagnosis
of COVID-19 and supplemented the equipment of health actors with
new machines. The company has been able to build up a catalog of
products among the most complete on the market in record time,
including:
- high-throughput automated PCR tests for the detection of
SARS-CoV-2, with the first CE-marked test in France from its Korean
partner Seegene and its proprietary tests from the EBX range, all
of these tests making it possible to detect all variants of the
coronavirus, both on nasopharingeal swab and saliva,
- tests for the identification and typing of the main variants of
SARS-CoV-2, complementary to existing PCR tests and which will be
launched for research use in the coming days,
- an antigenic test on instrument for hospital laboratories,
- a rapid proprietary antigen test, launched very recently and
intended for professional players in point of care medicine, in
particular pharmacists. and
- several serological tests, including neutralization tests
available to accompany the vaccination campaign.
Internationally, the company has signed several
agreements and contracts with distribution partners for the
marketing of its EBX proprietary range of molecular biology. Thus,
significant sales of the EBX SARS-CoV-2 test were achieved, and
there still are significant orders for the coming months.
Turnover excluding COVID increases + 22%
(+ 10% organically) at € 71.9 million
Very mobilized, in a context of organizational
constraints linked to confinements and the strong increase in
activity on COVID products, traditional activities recorded a solid
growth, with turnover of € 71.9 million, up 22 % compared to
2019.On a like-for-like basis, excluding sales related to acquired
subsidiaries, in particular TECOmedical on July 1, 2020, sales
excluding COVID increased over the year by 10%.
Eurobio Scientific has thus been able to meet
the demand for products unrelated to COVID-19 in a tense market
context disrupted by the fight against the epidemic. In France, the
company is benefiting, particularly in the disease division, from
the increase in the number of customers and in the installed
equipment base amplified by the need for automation linked to the
COVID-19 activity, and the continued development of molecular
biology.
The sustained growth of the classic activity
excluding COVID-19 confirms the resilience of Eurobio Scientific's
product lines as well as the relevance of its business model,
secured by the recurrence of its sales.
in € m |
2020 |
2019 |
var. |
COVID |
117 |
0,0 |
- |
Excluding COVID |
71.9 |
59.1 |
+22% |
Total |
188.9 |
59.1 |
+220% |
unaudited |
|
TECOmedical and Pathway Diagnostics'
non-COVID-19 sales were also strong. Highly specialized in the
fields of immunology and research products, these two recently
integrated subsidiaries had to get organized to meet the needs
linked to the epidemic. Therefore, during the second half of 2020,
Eurobio Scientific opened new microbiology departments in both
companies, in order to promote its proprietary molecular biology
offer in their respective geographic areas.This development is
starting to bear fruit with the signing of the first customer
contracts, particularly in Germany and UK, which should allow an
increase in sales of EBX proprietary products in the coming
months.
An exceptional year paving the way for an accelerated
strategic development
Beyond turnover, good management of the crisis
and increased activity had very positive impacts for Eurobio
Scientific, namely: a strengthened image, new customers in France
and abroad, a growing number of installed automates, and a higher
share of proprietary products sales. The Group expects a very
strong improvement in its results for the 2020 financial year,
leading to a very solid financial base with a cash position of
around € 65 million as of December 31, 2020, and around € 25
million of overall financial debt.
This increased visibility and these strengthened
resources will enable Eurobio Scientific to accelerate its
strategic deployment with the following specific
objectives: -
an increase in the share of proprietary products, thanks to new
investments in R&D and molecular
biology, -
the strengthening of international sales
team, -
the signing of new distribution partnerships,
and -
the pursuit of its targeted external growth strategy.
Next financial meeting2020 annual results:
April 14, 2021 (after market close)
About Eurobio Scientific
Eurobio Scientific is a key player in the field of specialty in
vitro diagnostics. It is involved from research to manufacturing
and commercialization of diagnostic tests in the fields of
transplantation, immunology and infectious diseases, and sells
instruments and products for research laboratories, including
biotechnology and pharmaceutical companies. Through many
partnerships and a strong presence in hospitals, Eurobio Scientific
has established its own distribution network and a portfolio of
proprietary products in the molecular biology field. The Group has
approximately 148 employees and three production units based in the
Paris region, in Germany and in the United States, and several
affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany
and Utrecht in The Netherlands. For more information, please
visit : www.eurobio-scientific.com The company is publicly
listed on the Euronext Growth market in Paris Euronext Growth BPI
Innovation, PEA-PME 150 and Next Biotech indices, Euronext European
Rising Tech label. Symbol: ALERS - ISIN Code: FR0013240934 -
Reuters: ALERS.PA - Bloomberg: ALERS:FP |
Contacts |
Group Eurobio Scientific Denis Fortier, General
Manager Hervé Duchesne de Lamotte, General Manager Tel. +33(0) 1 69
79 64 80 |
Calyptus Mathieu Calleux / Gregory Bosson
Investors relations Tel. +33(1) 53 65 68 68
eurobio-scientific@calyptus.net |
Disclaimer
This press release contains non-factual
elements, including, but not limited to, certain statements
regarding future results and other future events. These statements
are based on the current vision and assumptions of the management
of the Company. They incorporate known and unknown risks and
uncertainties that could result in significant differences in
results, profitability and expected events. In addition, Eurobio
Scientific, its shareholders and its affiliates, directors,
officers, counsels and employees have not verified the accuracy of,
and make no representations or warranties about, statistical
information or forecast information contained within this news
release and that originates or is derived from third party sources
or industry publications; these statistical data and forecast
information are only used in this press release for information
purposes. Finally, this press release may be drafted in French and
in English. In the event of differences between the two texts, the
French version will prevail.
- PR_Eurobio Scientific_CA_2020_EN
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Mar 2023 a Mar 2024